Narrative Enterocutaneous fistula (ECF) is an abnormal connection between the bowel and skin. It can be associated with discharge of pus, feces, and stomach contents and can even lead to incontinence. The foul enteric contents act as a chemical irritant to the skin, leading to skin breakdown and predisposition to infection. The current treatment paradigm is unsuccessful; high fistula discharge, infection, and chronic inflammation lead to high failure and recurrence rates. We aim to offer a solution in the treatment of potentially fatal ECF using a minimally invasive blood derived biomaterial-based platform to occlude the fistulous tract using groundbreaking injectable shear- thinning biomaterials with anti-microbial and regenerative properties.
|Effective start/end date||12/1/21 → 11/30/22|
- National Institute of Diabetes and Digestive and Kidney Diseases: $591,580.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.